T1	Entity 153 170	a control subject
T2	Entity 93 102	generated
T3	Entity 448 480	patient-specific cellular models
T4	Entity 668 681	staurosporine
T5	Cluster4 721 753	the serine/threonine kinase S6K2
T6	Entity 868 881	downregulated
T7	Cluster3 935 952	kinase inhibitors
T8	Entity 957 969	reduced S6K2
T9	Entity 975 982	rescued
T10	Cluster7 1025 1060	cell-autonomous, reversible defects
T11	Cluster9 1146 1182	PGRN-dependent pathogenic mechanisms
T12	Entity 1187 1194	testing
T13	Cluster10 1195 1214	potential therapies
T14	Cluster3 1457 1474	kinase inhibitors
T15	Cluster12 1447 1453	stress
T16	Cluster4 1477 1481	S6K2
T17	Entity 1485 1498	downregulated
T18	Cluster5 1502 1517	patient neurons
T19	Entity 1521 1544	a PGRN-dependent manner
T20	Entity 1804 1826	a human neuronal model
T21	Cluster6 1905 1916	these lines
T22	Entity 2124 2131	testing
T23	Entity 1248 1268	A human neuron model
T24	Entity 2055 2069	a model system
T25	Cluster9 2083 2119	PGRN-dependent pathogenic mechanisms
T26	Entity 1387 1392	iPSCs
T27	Entity 103 147	multiple induced pluripotent stem cell lines
T28	Entity 205 219	an FTD patient
T29	Entity 225 285	a novel heterozygous GRN mutation (progranulin [PGRN] S116X)
T30	Cluster2 484 507	PGRN haploinsufficiency
T31	Cluster8 583 601	PGRN S116X neurons
T32	Entity 611 631	sporadic FTD neurons
T33	Entity 517 536	a systematic screen
T34	Entity 643 664	increased sensitivity
T35	Entity 686 709	other kinase inhibitors
T36	Entity 770 849	the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways
T37	Cluster8 885 903	PGRN S116X neurons
T38	Entity 910 931	increased sensitivity
T39	Entity 986 1001	PGRN expression
T40	Cluster5 1064 1079	patient neurons
T41	Entity 1085 1100	PGRN deficiency
T42	Cluster2 1272 1309	progranulin (PGRN) haploinsufficiency
T43	Entity 1327 1386	Sporadic and PGRN-deficient frontotemporal dementia patient
T44	Entity 1404 1429	PGRN S116X mutant neurons
T45	Entity 1545 1573	Progranulin (PGRN) mutations
T46	Entity 1596 1619	frontotemporal dementia
T47	Cluster2 1830 1853	PGRN haploinsufficiency
T48	Entity 1866 1891	human postmitotic neurons
T49	Cluster7 1924 1962	cell-autonomous and reversible defects
T50	Entity 2018 2040	PGRN-deficient neurons
T51	Entity 0 58	The pathogenic mechanisms of frontotemporal dementia (FTD)
T52	Entity 172 181	a patient
T53	Entity 187 199	sporadic FTD
T54	Cluster6 1704 1789	multiple frontotemporal dementia patient-specific induced pluripotent stem cell lines
T55	Cluster10 2132 2151	potential therapies
T56	Entity 290 297	neurons
T57	Entity 302 311	microglia
T58	Entity 332 373	PGRN S116X induced pluripotent stem cells
T59	Entity 375 385	the levels
T60	Entity 389 420	intracellular and secreted PGRN
T61	Entity 540 548	inducers
T62	Cluster12 552 567	cellular stress
T63	Entity 1137 1145	studying
T64	Entity 1625 1659	the underlying molecular mechanism
T65	Entity 1966 1993	specific signaling pathways
T66	Entity 2074 2082	studying
T67	Cluster1 90 92	we
T68	Cluster1 1003 1006	Our
T69	Cluster1 569 571	we
T70	Cluster7 1994 1998	that
T71	Cluster11 1804 1853	a human neuronal model of PGRN haploinsufficiency
T72	Cluster11 1248 1309	A human neuron model of progranulin (PGRN) haploinsufficiency
